Cancer cells are known to experience a high level of stress and may require constant repair for survival and proliferation. Recent studies showed that inhibition of heat shock factor 1 (HSF1), the key regulator for the stress-activated transcription of heat shock protein (HSP), can reduce the tumorigenic potential of cancer cells. Such a "nononcogene addiction" phenomenon makes HSF1 an attractive cancer drug target. Here, the authors report an image-based high-content screening (HCS) assay for HSF1 functional inhibitors. A heat shock-based methodology was used to stimulate the stress response followed by quantitative measurement of HSF1/HSP70 granules for compound-induced inhibitory effects. The authors discovered a small molecule from a compound library that inhibits HSF1 granule formation substantially in heat-shocked HeLa cells with IC 50 at 80 nM. Electorphoretic mobility shift of HSF1 by this compound suggested significant inhibition of HSF1 phosphorylation, accompanied by reduced expression levels of HSP70 and HSP90 after heat induction. Importantly, HeLa cells stably transfected with HSF1 shRNA were more resistant to the compound treatment under lethal temperature than cells containing HSF1, further validating an HSF1-dependent mechanism of action. The HCS assay the authors developed was robust with a Z′ factor of 0.65 in a 384-well plate format, providing a valuable method for identifying small-molecule functional inhibitors of HSF1 for potential cancer treatment. (Journal of Biomolecular
INTRODUCTION
T arget-based cancer therapy has transformed conventional chemotherapy into a modern molecular approach that specifically attacks the oncogenic proteins or pathways. 1, 2 Genetic and epigenetic alterations can activate oncogenes whose activities are necessary for tumor initiation and maintenance, a phenomenon called "oncogene addiction." 3, 4 Significant efforts have been made with several target-based small-molecule drugs (Gleevec, Iressa, and Tarceva) and therapeutic antibodies (Herceptin, Erbutix, and Avastin) available for cancer patients. 2 Clinical success of these therapies has provided reasonable assurance for future target-based cancer drug development. 3, 4 "Nononcogene addiction" is another type of phenomenon whereby critical proteins do not activate known oncogenic pathways through gene mutations or overexpression but are otherwise essential for the survival of the transformed cells. Targeting this large class of molecules may lead to equally if not better therapeutic impact than that of oncogene pathways. 3, 4 Heat shock factor 1 (HSF1) is the master transcription factor responsible for controlling the heat shock response. 5 HSF1 is normally maintained in an inactive monomeric state through binding to a complex containing heat shock protein (HSP) 90 and HSP70. When cellular stress occurs by any of the multiple known causes of protein misfolding (such as heat shock), HSF1 dissociates from the chaperone complex, translocates into the nucleus, and forms active phosphorylated trimers. Activation of HSF1 leads to the induction of HSP70 and other chaperone family proteins, a highly conserved protective mechanism by which the stressed cells can repair misfolded proteins or deliver them to proteasome for destruction. 5, 6 Cancer cells are known to experience high levels of DNA damage, aneuploidy, and reactive oxygen species, which makes them particularly dependent on the heat shock pathway for survival. [3] [4] [5] [6] Dai and colleagues 7 recently reported that HSF1 plays an important role in the generation and maintenance of cancer cells. Their study demonstrated that genetic HSF1 deficiency in transgenic mice inhibits tumorigenesis in a chemically induced skin carcinogenesis model and also in genetic models containing oncogenic mutations of the RAS oncogene or inactivating mutations in the tumor suppressor p53. Importantly, shRNA knockdown of HSF1 in several human cancer lines confirmed that tumor cells have a much greater dependence on HSF1 function compared to normal cells, suggesting that cancer cells are "HSF1 addicted." 7 HSP90 has recently emerged as an exciting target for cancer treatment. [8] [9] [10] Client proteins of HSP90 are key oncogenic players, including mutant p53, ERBB2, B-RAF, C-RAF, HER2, and CDK4. Inhibition of HSP90 can block multiple overlapping survival pathways used by cancer cells. 10 However, HSP90 inhibitors also induce HSP70, a chaperone that is known to be antiapoptotic. This mechanism-based HSP70 induction may limit the anticancer potential of HSP90 inhibitors. 8 Consistent with this view, it has been reported that HSF1-deficient mouse fibroblasts are more sensitive to 17-AAG, a clinical stage HSP90 inhibitor, than their wild-type counterparts. 11 Recent siRNA studies targeting HSF1 or HSP70 also demonstrate the improved cytotoxicity in human cancer cell lines for 17-AAG when potentially the induction of these compensatory responses to HSP90 inhibition is prevented. 12, 13 Therefore, pharmaceutical inhibition of HSF1, a validated "nononcogene" cancer drug target, provides an attractive opportunity for target-based therapeutics. 3 HSF1 is broadly distributed throughout the cell when inactivated but forms distinguished granules within the nucleus of stressed cells when transcriptionally activated, a phenotypic change that correlates well with HSF1 activity. 14, 15 HSP70, one of the most abundant chaperone proteins, also becomes highly concentrated in the nucleoli as HSP70 granules after the stress of heat shock. 16, 17 We have previously demonstrated that both HSF1/HSP70 granules can be quantified with image-based analysis for large-scale screening of compounds that amplify the heat shock response. 18 In this study, we developed and validated a high-content screening (HCS) method that can evaluate the potency of compounds by their ability to decrease the formation of the HSF1/HSP70 granules generated by heat shock stress. Our initial screening efforts led to the discovery of a compound that inhibits HSF1/HSP70 granule formation substantially with nanomolar potency. Further analysis strongly suggested that this compound significantly inhibits HSF1 phosphorylation after heat shock. In addition, this compound profoundly decreased survival of heat-shocked cells, but shRNA knockdown of HSF1 largely reduced this effect, validating an HSF1-dependent mechanism of action.
MATERIALS AND METHODS

Compound library
An in-house collection with 1300 compounds was selected for screening. We routinely checked the purity of compounds by liquid chromatography/mass spectrometry (LC/MS). Compounds in master plates were prepared at a concentration of 10 mM in DMSO. Positive controls were placed in column 1, and DMSO controls were in column 12 in V-bottomed 96-well plates (Costar 3363). All compound plates were stored in -20 °C freezers.
Reagents and cell lines
All reagents were of analytical grade. Triptolide was purchased from EMD Biosciences (San Diego, CA). Paraformaldehyde was purchased from EMS (Hatfield, PA). HSF1 polyclonal antibody (catalog SPA-901), HSP70 monoclonal antibody (catalog SPA-810), and HSP90 antibody (for HCS, catalog SPA-830) were obtained from Stressgen (Ann Arbor, MI). HSP90 monoclonal antibody (for Western blot, catalog 610418) and Actin monoclonal antibody (catalog 612656) were purchased from BD Biosciences (San Jose, CA). PhosphoSer 326 -specific goat polyclonal antibody was custom-made from Invitrogen (Carlsbad, CA) with a peptide sequence of CSVDTLLpSTAL. 19 FITC-labeled antimouse antibodies (catalog 115-096-146) and rhodamine-labeled antirabbit antibodies (catalog 711-295-152) were purchased from Jackson ImmunoResearch (West Grove, PA). HeLa cells were purchased from ATCC (Manassas, VA). All cells were cultured in modified Eagle's medium (MEM) with 10% fetal bovine serum (FBS; v/v) and 10 mM L-glutamine. Cells were subcultured using 0.05% trypsin-EDTA when confluence was estimated at 80% to 90%. Subcultured cells within 10 passages were routinely used for HCS assay and Western blot study.
Construction of stably transduced HSF1 knockdown HeLa cells
To generate the retroviruses encoding HSF1 shRNA or a vector control, GP2-293 cells were cotransfected with pSI-REN-HSF1 shRNA (a generous gift from Dr. Michael Y. Sherman, Boston University School of Medicine 20 ) or pSIREN-NC shRNA (Clontech, Mountain View, CA), together with pVSV-G (Clontech), using Clonfectin transfection reagent (Clontech). Culture supernatants that contain retroviral vectors were collected 72 h posttransfection. HeLa cells were infected with RetroQ-NC shRNA or RetroQ-HSF1 shRNA retroviruses. Forty-eight hours after infection, infected cells were selected by the addition of 1 µg/mL Puromycin. Five days after Puromycin selection, cell lysates of resistant populations were collected for Western blot validation of HSF1 knockdown.
Heat shock stress
Cells were pretreated with compounds 1 h before heat shock at 43 °C for 2 h. To avoid the edge effects caused by heat shock, a custom-made aluminum plate was prepared to achieve constant temperature for the entire 96-well or 384-well plate. The aluminum plate was kept inside incubator at 43 °C the day before experiment. Recovery condition was set to incubate at 37 °C for 0 (R0, no recovery time), 2 h (R2), 4 h (R4), 6 h (R6), and 24 h (R24). 1 . HeLa cells were seeded in Costar 384-well assay plates (Costar 3712) at a density of 2000 cells/well approximately 16 to 24 h before compound treatment. The overall dilution of compound in MEM was 1000-fold, with a final concentration of 10 µM for screening (final DMSO concentration is 0.25% v/v). The compound was washed out during the cell-fixing procedure. 2. Cells were heat shocked at 43 °C for 2 h followed by immunocytochemical staining according to published protocols with some modifications. 18, 21 For HSF1, cells were fixed immediately after heat shock with no recovery time (R0); for HSP70 or HSP90, cells were fixed 0, 2, 4, and 6 h after heat shock, respectively. 3. Detailed procedure for cell fixation and permeabilization:
Outline of multiplexing immunocytochemical assay
25 µL of 16% paraformaldehyde was mixed with the culture medium (total volume at 100 µL) to a final concentration of 4%. The plates were incubated at room temperature for 30 min before washing with phosphate-buffered saline (PBS). Permeabilization of cellular membrane was achieved using 0.2% Triton X-100 in PBS for 30 min. After washing 3 times with PBS, 20 µL of 5% FBS/PBS was applied to the plates at room temperature for 1 h. 4. Multiplexing antibody staining: DAPI/HSF1 (rhodamine)/ HSP70 (FITC) tricolor combination was performed throughout the study. To further understand the dynamics of HSP70 and HSP90 after HSF1 inhibition, we also performed DAPI/HSP70 (rhodamine)/HSP90 (FITC) multiplexing experiments. Briefly, a 1:500 dilution of anti-HSF1 and anti-HSP70 or anti-HSP90 antibody in 1% FBS/PBS was added to the plates. The plates were incubated at room temperature for 2 h or at 4 °C overnight. Finally, a mixture of DAPI, FITC, or rhodamine-labeled secondary antibody was added to the plates at a final concentration of 1:2000 (for DAPI at 5 mg/mL) and 1:500 (for FITC-labeled antimouse antibodies or rhodamine-labeled antirabbit secondary antibodies). After a 1-h incubation at room temperature, the plates were washed with PBS and stored at 4 °C. All robotic operation was performed with Sciclone ALH 3000 (Caliper Life Sciences, Hopkinton, MA).
High-content image acquisition and data analysis
Image acquisition and analysis were performed using an INcell 1000 (GE Healthcare, Piscataway, NJ) integrated with a Twister II (Caliper Life Sciences) for automated plate delivery. The setting for image acquisition was 3 images captured per well at 500 ms for DAPI and 100 ms for FITC or rhodamine. Image analysis was carried out using algorithms developed for HSF1/HSP70 granule count, granule area, nuclear intensity coefficient of variation (CV), and HSP70/HSP90 total intensity (cellular and nuclear intensity combined) with the Multi Target Analysis (MTA) module from Workstation 3.6 (GE Healthcare). The percentages of HSF1 and HSP70 granule-positive cell (GPC) were calculated using MTA with the gating values equivalent to the average of DMSO-treated samples minus 2 or more standard deviations. Relative cell viability was calculated with cell count recorded in the DAPI channel of HCS screening using the following formula: relative cell viability = (average of cell count compound /Average of cell count DMSO ) × 100%. IC 50 calculation and curve fitting were performed using Prism 4.0 (GraphPad Software, San Diego, CA) with nonlinear regression analysis, where the IC 50 value equals the concentration at which the inflection point of the fitted model is reached. Z′ factor was calculated using the following formula:
where µ and σ are the mean and standard deviation, respectively, of both positive control (p) and negative control (n).
MTS assay
MTS assay was performed as previously described. 18 Briefly, HeLa cells with HSF1 knockdown (HeLa-HSF1 shRNA) or HSF1 nonknockdown control (HeLa-vector shRNA) were seeded in 96-well plates (catalog Costar 3598, Corning, Lowell, MA) with a density at 5500 cells/well and incubated overnight. Compounds were diluted in MEM to designated concentrations (final DMSO concentration is 0.5% v/v). Cells were incubated with selected compounds for 2 h before heat shock at 45 °C for 30 min followed by a 24-h recovery time. MTS/PMS were added to the culture medium for 3 h. Sodium dodecyl sulfate (SDS) was then added to a final concentration of 1.25% (w/v %) to stop the reaction. Plates were measured for absorbance at 492 nm using EnVision Excite (PerkinElmer, Wellesley, MA). The absorbance (A) at 492 nm is directly proportional to the viable cells in the culture. Percent inhibition was calculated using the following formula:
IC 50 values and curve fitting were calculated as described previously.
Western blot analysis
HeLa cells were seeded at a density of 2.5 × 10 5 in 6-well plates with MEM plus 10% FBS overnight. After pretreatment with compounds for 2 h, cells were heat shocked at 43 °C for 2 h with 0-h recovery (for HSF1) or 24-h recovery (for HSP70 and HSP90). Western blotting was performed with 1:1000 dilution of primary antibodies to total HSF1 and p-Ser326 HSF1 and 1:10000 dilution of secondary antibodies. Image scanning and quantification were performed with an Odyssey infrared imaging system (Li-Cor Biosciences, Lincoln, NE) according to the manufacturer's instructions.
RESULTS
Triptolide as a positive control for HCS assay development
Several small molecules were previously reported as inhibitors of the heat shock response pathway, including quercetin, 22 KNK437, 23 and triptolide, 24 with triptolide being studied in most detail. Westerheide and colleagues 24 reported that triptolide does not inhibit the earlier steps in the HSF1 multistep activation process, including trimer formation, hyperphosphorylation, or translocation and binding HSP70 promoter. The inhibitory effect of triptolide on HSP70 expression was reported to be at the level of transcription by interfering with the proper activity of the C-terminal transactivation domain of HSF1.
We reasoned that triptolide, a proven inhibitor of HSF1 activation, 24 might disrupt granule formation of HSF1 and act as our positive control. To confirm this hypothesis, we performed a high-content image-based assay with HeLa cells pretreated with different concentrations of triptolide. Sublethal stress conditions of 43 °C for 1 to 4 h were applied to the samples. Decrease of percent HSF1 granule-positive cells (HSF1 GPC%), HSF1 granule count per cell, total nuclear intensity, and total granule area all gave similar results with this and other compounds (data not shown). Quantification of granule number was favored because the HSF1 granule number is known to correlate with HSF1 transcriptional activity. 14, 15 Furthermore, granule count data were more consistent between experiments, whereas total nuclear fluorescent intensity and granule area were more variable. HSF1 GPC% was selected over granule counts per cell because the percentage of HSF1 granule-positive cells had a lower CV compared to that of granules per cell. The threshold for HSF1 GPC% was the mean HSF1 granule count of DMSOtreated control samples minus 2× the standard deviation, which is 5.0 granules/nucleus. Thus, HSF1 GPCs (granule positive cells) are cells with 5 or more HSF1 granules per nucleus, similar to DMSO-treated control samples, whereas granule-negative cells are cells with fewer than 5 granules per nucleus, similar to positive control (triptolide) treated samples. So in a measured cell population, GPC% can be used to evaluate the inhibitory effects induced by compound. For HSF1 at R0 with a 2-h heat shock time, 37.16% ± 3.12% GPC and 31.86% ± 1.5% GPC were recorded with 1 µM and 10 µM triptolide treated, respectively, significantly lower compared to DMSO-treated controls with 55.17% ± 3.12% GPC (Fig. 1A) . Less reduction in GPC% was recorded when 0.01 µM or 0.1 µM triptolide was applied to the heat-shocked cells. Similar results for HSF1 GPC% were also observed at 3-and 4-hour heat shock time points.
For HSP70, we performed HCS experiments at 2 recovery time points after a 2-h heat shock, including R4 (recovery at 4 h) and R6 (recovery at 6 h), to allow time for transcription and translation of HSP70. Highly significant reduction of HSP70 GPC% at both R4 and R6 time points was observed with the treatment of 100 nM or more triptolide (Fig. 1B) . For example, HSP70 GPC% at R4 was recorded at 43.34% ± 3.81% for DMSO controls but decreased to 11.66% ± 1.31% when treated with 0.1 µM triptolide. Figure 1C shows representative images of HeLa cells treated with 10 µM triptolide as compared with DMSO-treated controls. Therefore, both HSF1 and HSP70 granule formation after heat shock are indeed inhibited by triptolide HSF1 granule formation was recorded after heat shock at 43 °C for 2 h at R0, and HSP70 granule formation was recorded at R4. in a dose-dependent manner, making it useful as an initial positive control for HSF1 inhibition assay development.
High-content primary screen for HSF1 inhibitors
We next performed a pilot screen with a compound collection containing 1300 bioactive molecules at 10 µM concentration. The assay was performed in a 384-well format with the heat shock condition set at 43 °C for 2 h. We did not obtain a satisfactory Z′ value due to relatively weak activity of triptolide. Thus, the purpose of our screen is to identify not only potent hits but also a better positive control for this assay. Figure 2 shows a 2D presentation of screening results using Spotfire software (TIBCO Spotfire, Somerville, MA) with the x-axis for percent relative viability and the y-axis for HSF1 GPC%. More than 40 compounds showed less than 30% of HSF1 GPC, which may be a potential chemical collection for HSF1 inhibition. We decided to use 10% HSF1 GPC, which is a 5-fold reduction from the DMSO control, as a cutoff value for selection of potent HSF1 inhibitors. Because HeLa cells were exposed to compounds at 10 µM for only 3 h in our HCS primary assay, we considered compounds with significant loss of cells as general cytotoxic agents. Taking advantage of the multiplexing nature of HCS, we obtained cell counts from the DAPI nuclear staining channel and removed compounds with less than 80% of cell viability compared to the average of DMSO-treated controls. Seven compounds met our HSF1 inhibition and viability criteria (Fig. 2, labeled in red) and were advanced for the dose-response study. Three of the 7 compounds were confirmed with submicromolar to micromolar IC 50 values. Among them, compound 1 exhibited substantial inhibition with an IC 50 of 80 nM for HSF1 inhibition at R0 and 130 nM for HSP70 inhibition at R4 (Fig. 3) . Compound 1 was therefore selected for further hit confirmation and mechanism of action study. Figure 4A shows the multiplexing HCS time course study for compound 1 up to 24-h recovery time after heat shock. Pretreatment 1 h before heat shock with 0.1 µM compound 1, a concentration close to its IC 50 value, significantly reduced HSF1 GPC% from 58.37% ± 1.51% (DMSO control) to 30.33% ± 4.40% at the R0 time point. With time, HSF1 GPC% gradually decreased to a basal level of 0.65% ± 0.37% at the R24 hour time point. It should be noted that HSF1 GPC% for compound 1-treated cells was always lower than that of the DMSO-treated control.
Compound 1 decreases HSF1 granules and lowers HSP protein levels after heat shock
We also simultaneously measured the effects of compound 1 on steady-state total cellular protein levels of HSP70 and HSP90, two major HSF1 transcriptionally regulated chaperone proteins. Positively stained cells (PSCs) were designated as cells with higher total intensity (both cellular and nuclear signal) than the defined threshold (average of DMSO control samples minus 2 folds of standard deviation). As shown in Figure 4A , PSC% in the presence of compound 1 for both HSP70 (42.8% ± 6.4%) and HSP90 (15.1% ± 4.9%) 24 h after heat shock was significantly lower than that of the corresponding heat-shocked Seven compounds (labeled in red) were selected with a desired biological profile that HSF1 GPC% is below 10% and relative cell viability is above 80% when normalized to DMSO-treated samples. Also, 1 µM triptolide and DMSO were used as positive control and negative control with their HSF1 GPC% (average ± standard deviation) shown in the inset. Each data point equals the mean ± standard deviation, n = 2. DMSO control cells (79.72% ± 5.67% and 47% ± 4.53%, respectively). Compared with the HSP total protein levels, HSP70 granule count was also evaluated, with data correlating well in the R2 to R4 timeframe (data not shown). Interestingly, disruption of the HSF1 granules by compound 1 had kinetically different effects on the accumulation of HSP70 compared to HSP90 (Fig. 4A) . Compound 1 appeared to immediately prevent the heat shock-induced accumulation of HSP70 protein observed in the DMSO control. However, by 24 h, the level of HSP70 had slowly increased to approximately half the level of the DMSO control, possibly suggesting a delayed HSF1 granule-independent compensatory mechanism for HSP70 expression. Conversely, compound 1 demonstrated only a relatively small inhibition of the initial heat shock-induced accumulation of HSP90 but seemed to prevent the sustained response to heat shock. The steady-state HSP90 protein levels decreased more rapidly after the first 2 h and approached basal levels by 24 h compared to the DMSO control, which still had approximately 3-fold more HSP90 than that of compound 1-treated cells (Fig. 4A) .
We also observed interesting patterns of multiplexing data of these two chaperone proteins (Fig. 4B) with representative images shown in Figure 4C . At R4, HSP70+HSP90+ cells accounted for 46.34% in DMSO control samples, whereas only 33.62% of HSP70+HSP90+ cells were recorded in 0.1 µM compound 1-treated samples. Meantime, the population of HSP70-HSP90-cells was significantly increased from 34.32% (DMSO control) to 49.89% (compound 1-treated sample, Fig.  4B ). There were no major changes in the categories of HSP70+HSP90-and HSP70-HSP90+, suggesting that compound 1 inhibits cellular HSP70 and HSP90 expression in a synchronized fashion, most likely through HSF1 inactivation. Similar results were obtained at R24 with HSP70+HSP90+ cells being further reduced to 12.67% after treatment of compound 1. The majority of cells (50.26%) belonged to the category of HSP70-HSP90-, although a modest increase (7%) of HSP70+HSP90-cells was observed, indicating that the recovery of HSP70 expression was faster than that of HSP90. Interestingly, there were essentially no cells after 24-h recovery from heat shock, with or without compound 1, that expressed HSP90 in the absence of HSP70 (Fig. 4B, HSP70-HSP90+ ). Conversely, large numbers of cells expressed HSP70 in the absence of HSP90 (Fig. 4B, HSP70+HSP90-) . One possible explanation for these data is that HSP70 is necessary but not sufficient to restore the pre-stress-induced levels of HSP90 or vice versa or both. This hypothesis is consistent with the kinetics of protein expression levels in Figure 4A , where the increase in HSP70 protein levels seemed to correlate with the decrease in HSP90 levels. Nevertheless, both fluorescent signals from HSP70 and HSP90 were maintained at a relatively low level (compared to DMSO control) 24 h after completion of heat shock.
Western blot confirmation
Protein immunoblotting was performed to investigate decreased HSF1 functional activity and also confirm decreased protein levels of HSP70 and HSP90 by compound 1 observed in high-content multiplexing analysis. Stress-dependent activation of HSF1 is known to be dependent on a resultant hyperphosphorylation, which decreases its electrophoretic mobility ("super-shift"). As expected, 2-h heat shock at R0 resulted in a dramatic HSF1 super-shift in heat-shocked cells compared to nonstressed cells (Fig. 5) . However, heat-shocked cells treated with compound 1 exhibited a dose-dependent decrease in the HSF1 super-shift compared to DMSO controls (Fig. 5) . Moreover, we also observed a significant dose-dependent decrease of phosphorylation levels of Ser326, a known inducible phosphorylation site when HSF1 activates. 19 Thus, the mechanism by which compound 1 inhibits functional activity of HSF1 may be through inhibition of a kinase or activation of a phosphatase that dec reases the levels of phosphorylation, particularly at Ser326, known to be necessary for the functional activity of HSF1. 5, 14, 19 Alternatively, compound 1 might directly or indirectly alter the conformation of HSF1, which then becomes less accessible to kinase or more accessible to phosphatase.
Concomitant with the inhibition of the stress-dependent super-shift of HSF1 was a reduction of both HSP70 and HSP90 protein expression compared to DMSO-treated samples at the R24 recovery time point, consistent with HCS analysis (Fig. 5) . Western blot analysis of HeLa cells treated with compound 1 at concentrations indicated after heat shock at 43 °C for 2 h with no recovery (for HSF1 and p-Ser326 HSF1) or with recovery time at 24 h (for HSP70 and HSP90). Samples with no heat shock (37 °C) were used as controls. Arrow indicates super-shift of HSF1 bands when HSF1 becomes phosphorylated after heat shock. Ser326 is a stress-inducible phosphorylation site in HSF1. 19 Actin was used as a loading control.
At R4, we also noticed the reduction of HSP70 protein expression but not in HSP90 expression level (data not shown). Thus, the subtle change of expression levels at the early recovery time point (R4 or earlier) can be monitored by the more sensitive HCS platform (Fig. 4A,B) but not by the conventional Western blot assay.
HSF1 dependency for compound 1 activity confirmed by shRNA knockdown
Because compound 1 showed dramatic inhibition of the stress response, it was expected that the compound should increase cellular sensitivity to stress. Furthermore, it was particularly important to validate that HSF1 is the target responsible for compound-induced stress-hypersensitivity in cancer cells. To address these questions, we constructed a matching pair of HeLa cell lines stably transduced with a retroviral vector that contained either shRNA to specifically knock down HSF1 expression (HeLa-HSF1 shRNA) or a vector control lacking the shRNA with normal HSF1 levels (HeLa-vector shRNA). Our Western blot results confirmed that more than 90% of HSF1 was depleted in the HeLa-HSF1 shRNA line compared to the HeLa-vector shRNA line (Fig. 6A) .
In experiments with lethal heat shock conditions of 45 °C for 30 min, we observed 21% ± 2.5% cell killing in HeLavector shRNA-carrying cells and 52.21% ± 4.6% cell killing in HeLa-HSF1 shRNA-carrying cells after 24 h of recovery (Fig.  6B) . Thus, knockdown of HSF1 resulted in a net 31% increase in heat shock cytotoxicity and confirms the importance of HSF1 in protection from heat shock damage. We then tested cell viability of this cell pair 24 h after exposure to lethal heat shock in the presence of either DMSO as a control or various concentrations of compound 1. HSF1 functional inhibitor compound 1 caused significantly more cytotoxicity compared to DMSO controls in HeLa-vector shRNA control cells than that of HeLa-HSF1 shRNA cells lacking HSF1 (Fig. 6C) . Compound 1 exhibited a differential cytotoxic profile in the HSF1 knockdown study with an IC 50 value of 0.16 µM for HeLa-vector shRNA and no obvious additional cytotoxicity recorded in the HeLa-HSF1 shRNA line. The fact that compound 1 increased heat shock-induced cell death only in the presence of HSF1 further confirmed an HSF1-dependent mechanism of action.
High-throughput robotic operation for compound screening
Using the Sciclone ALH 3000 robotic liquid-handling system, we have proven the adaptability of this assay for automatic operation in a 384-well plate format. An average Z′ of 0.65 was obtained for this assay with a satisfactory signal/noise of 11.25 and a relatively low CV of 12% (Fig. 7A) . The assay was also evaluated for over a period of 6 weeks with a consistent Z′ value calculated for compound 1 (Fig. 7B) . The Table  summarizes the calculated Z′ factors for HSF1/HSP granule assays when compound 1 was used as a positive control. Z′ factors are more than 0.5 for compound 1 in all 4 conditions tested, including HSF1 GPC% and HSP70 GPC%, validating this assay for large-scale primary screening with compound 1 as an assay control.
DISCUSSION
We developed a high-content image-based assay for HSF1 functional inhibitor screening and further identified a compound that inhibits the activity of HSF1 in cancer cell culture. Compared to conventional reporter-based assays, our HCS platform exhibited several advantages:
1. Biological relevancy. HSF1 and HSP70 granule formation are well accepted indicators for HSF1/HSP70 functional activity, not just transcription or protein levels of a single HSP. [14] [15] [16] [17] [18] Our assay directly measures HSF1 functional activity in cell culture, instead of reliance on a single gene promoter/reporter pair for a reporter system or a complicated in vitro promoter binding assay that may have no relevance to the cell. Reporter assays require the selection of a single transcriptional promoter (usually HSP70), which may give a misleading result if it does not contain all of its regulatory sequences or if it is not transcribed in its normal chromosomal location.
Simplicity with fewer sources of variability. Unlike
reporter-based assays that require vector construction and cell line transfection, cell line modification is not needed for the HCS assay. This largely eliminates potential variation caused by engineered cell lines as well as the associated cost and time delay. 3. Multiplexing. Our HCS platform can simultaneously monitor up to 4 different cellular markers in the heat shock response pathway, such as HSF1 activity, HSP70 and HSP90 protein levels, and viability by DAPI staining. In this way, we can be sure that a transcriptional regulator of HSF1 has the expected corresponding effects on steadystate protein expression levels of multiple HSPs. Future studies could utilize this advantage by detecting multiple HSF1 (different phosphorylated isoforms) or other HSPs (such as HSP27, 40, 110, etc.). Detailed study in the multiplexing format will help to further deconvolute the underlying molecular mechanisms. 4. Readiness for high-throughput robotic operation. The assay has an acceptable Z′ factor in the 384-well plate format ( Fig. 7) , allowing us to screen 10,000 to 20,000 compounds and process the multiplexing data in a week.
Our screen identified 3 confirmed hits out of a library of 1300 compounds. We used compound 1 as an example for further hit validation. We demonstrated that compound 1 reduced HSF1 activity, presumably by lowering its level of phosphorylation; reduced steady-state HSP70 and HSP90 protein levels; and increased stress-induced cell killing in an HSF1-dependent manner. These results confirm the utility of this HCS assay for the identification of HSF1 functional inhibitors. Furthermore, our results indicated that both HSP70 and HSP90 are downregulated by compound 1, an advantage over potential cancer treatments by HSP90 inhibitor alone, whose ability to specifically kill cancer cells could be compromised by the known induction of HSP70. 8 Another possibility is that HSF1 inhibition may synergize with HSP90 inhibition or with conventional chemotherapy. Our next step is to test HSF1 functional inhibitors obtained from the HCS platform in relevant cancer animal models. 
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